Luforbec® 100/6 (beclometasone 100mcg / formoterol 6mcg) pMDI, first branded generic alternative to Fostair® 100/6 pMDI to treat Asthma & COPD, is now available in the UK

Luforbec^® 100/6 (beclometasone 100mcg / formoterol 6mcg) pMDI, first branded generic alternative to Fostair^® 100/6 pMDI to treat Asthma & COPD, is now available in the UK

Lupin continues their commitment to providing new treatment choices to patients and supporting the NHS with this addition to the management of Asthma & COPD

Slough, UK, August 24, 2021: Lupin Healthcare, the UK-based wholly owned subsidiary of Lupin Limited (Lupin) today announced that, following Marketing Authorisation earlier this year, it has launched Luforbec (beclometasone/formoterol) 100/6 dose pressurised metered dose inhaler (pMDI), making it available now to patients in the UK, with the potential to offer significant cost savings for the NHS.1,2

Luforbec is indicated for the treatment of adult asthma and for the symptomatic treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 <50% predicted normal).³ Luforbec has the same licensed indications as Fostair® 100/6 pMDI,3,4 the same active ingredients, an extrafine formulation, and similar device characteristics.3,4,5

In the 12 months to May 2021, the NHS spent over £177 million on Fostair® 100/6 pMDI.6 Luforbec will offer a cost saving of £8.80 per prescription.^1,2

“Lupin is dedicated to serving both patients and healthcare providers with high quality medicines that address patient needs and deliver value. We are extremely pleased Luforbec is now available in the UK offering a treatment alternative for healthcare professionals at a reduced cost,” said Ben Ellis, General Manager – Lupin Healthcare UK.

Respiratory diseases affect one in five people. It is the third biggest cause of death in the UK and is a clinical priority for the NHS.⁷ In the UK, around 5.4 million people are currently receiving treatment for asthma, which is equivalent to one in every 12 adults.⁸ An estimated 1.2 million people are also living with COPD and this number is only set to increase.⁹ Asthma and COPD place a heavy cost burden on the NHS, estimated at £3 billion and £1.9 billion per year, respectively.⁷

“Considering the prevalence of asthma and COPD in the UK and the number of patients for   whom a pMDI is the most appropriate inhaler, I welcome the availability of an alternative pMDI option licensed with a spacer for my patients,” commented Darush Attar-Zadeh, Respiratory Lead Pharmacist, North Central London Clinical Commissioning Group (Barnet Borough).

About Luforbec 100/6 pMDI³

Luforbec is indicated in the regular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist (ICS/LABA)) is appropriate. This includes patients not adequately controlled with ICS and ‘as needed’ inhaled short-acting beta2-agonist or patients already adequately controlled on both ICS and LABA. Luforbec is indicated for symptomatic treatment of patients with severe COPD (FEV1 < 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.

About Lupin UK

Lupin Healthcare is a subsidiary of the global pharmaceutical company Lupin Limited which has a presence in over 100 countries and is the 3rd largest pharmaceutical company in the USA by prescriptions.¹⁰ Lupin’s heritage lies in generic medicines and delivering quality medicines and value to patients and healthcare providers. Lupin has a resilient supply chain with excellent supply history as well as having tried and tested continuity plans in place. Entrepreneurial spirit, external focus and pipeline strength elevate Lupin Healthcare from a standard generics company to a more specialist organisation, partnering with the NHS to deliver value in the anti-retroviral, women’s health, neuroscience and respiratory space.

www.lupinhealthcare.co.uk/

For further information please contact:

1 NHS BSA. Drug Tariff. https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/drug-tariff  Accessed August 2021.

    ² Luforbec 100 micrograms/dose/6 micrograms/dose inhaler. Lupin Healthcare (UK) Ltd. NHS dm+d browser. Available at:   https://services.nhsbsa.nhs.uk/dmd-browser/amp/view/162070%20?ref=YW1wTmFtZT1sdW%20ZvcmJlYyZzZWFyY2hUeX%20BlPUFNUA%3D%3D#ampSummary Accessed August 2021

³Luforbec 100/6 pMDI. Summary of Product Characteristics (SPC). Lupin Healthcare UK Limited. https://www.medicines.org.uk/emc/product/12639/smpc Accessed August 2021

4 Fostair 100/6 pMDI. Summary of Product Characteristics (SPC). Chiesi Ltd. https://www.medicines.org.uk/emc/medicine/21006#gref Accessed August 2021

5 Lupin Healthcare Limited. Data on File. UK-LUF-2104-00004

⁶ General Practice Prescribing Data June 2020 - May 2021 This public sector information is licensed under the Open Government Licence v3.0 (http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3). The NHS Business Services Authority (BSA) is the provider of the England data. NHS Wales Shared Partnerships Services is the provider of the Wales data. The Business Services Organisation is the provider of the Northern Ireland data. Public Health Scotland is the provider of the Scotland data

7 NHS. Respiratory Disease. https://www.england.nhs.uk/ourwork/clinical-policy/respiratory-disease/. Accessed August 2021.

8 Asthma UK. Understanding Asthma. https://www.asthma.org.uk/advice/understanding-asthma/what-is-asthma/. Accessed August 2021

9 British Lung Foundation. Our COPD research. https://www.blf.org.uk/research/our-impact/our-copd-research. Accessed August 2021.

10 IQVIA MAT Dec 2020 https://www.lupin.com/portfolio/lupin-quarter-iii-fy2021-results. Accessed August 2021.